Zydus and Synthon’s entry into a high-value collaboration on palbociclib tablets is amped up with a paragraph IV certification, which may lead to a 180-day market exclusivity.
Zydus Lifesciences has joined forces with Synthon by signing an exclusive licensing and supply agreement for palbociclib. While Synthon will be responsible for the manufacturing, supply, and US Food and Drug Administration registration, Zydus will take care of the drug’s commercialization in the US market.
The kinase inhibitor is a generic version of Pfizer’s oral breast cancer drug Ibrance, which is approved for the treatment...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
